Pappas Ventures provides investment in the life sciences sector.
Business Model:
Revenue: $4.8M
Employees: 2-10
Address: 2520 Meridian Pkwy
City: Durham
State: NC
Zip: 27713
Country: US
Pappas Ventures specializing in seed, start-ups, early, mid and growth capital investments.
Contact Phone:
+19199983300
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
6/2015 | Milestone Pharmaceuticals | Series B | 0 |
5/2011 | CardioDx | Private Equity Round | 60M |
8/2006 | LipoScience | Series F | 13M |
8/2009 | Biosyntech | Venture Round | 1.4M |
8/2010 | CeNeRx BioPharma | Series C | 0 |
9/2006 | Anthera Pharmaceuticals | Venture Round | 0 |
11/2013 | Envisia Therapeutics | Series A | 25M |
5/2005 | Bayhill Therapeutics | Series B | 35.4M |
5/2013 | Lumena Pharmaceuticals | Series A | 23M |
6/2011 | TESARO | Series B | 101M |
8/2016 | Rotation Medical | Series B | 12M |
7/2014 | Rotation Medical | Series B | 27.2M |
8/2008 | Anthera Pharmaceuticals | Venture Round | 0 |
2/2012 | CeNeRx BioPharma | Series D | 4.6M |
3/2014 | Lumena Pharmaceuticals | Series B | 45M |
5/2004 | NuVasive | Venture Round | 9.8M |
5/2010 | CardioDx | Series D | 34.5M |
4/2007 | Syndax Pharmaceuticals | Series A | 40M |
9/2012 | IlluminOss Medical | Series C | 0 |
4/2013 | Afferent Pharmaceuticals | Series B | 5M |
3/2015 | Thrasos | Series D | 21M |
10/2012 | Thrasos | Series C | 35M |
6/2011 | Ultragenyx Pharmaceutical | Series A | 45M |
8/2009 | Barosense | Series D | 27M |
6/2007 | Cequent Pharmaceuticals | Series A | 9M |
10/2018 | VelosBio | Series A | 58M |
3/2010 | Syndax Pharmaceuticals | Series A | 9M |
4/2006 | Bayhill Therapeutics | Venture Round | 15.8M |
1/2010 | Liquidia Technologies | Series C | 20M |
7/2012 | CardioDx | Private Equity Round | 0 |
7/2017 | Kezar Life Sciences | Series B | 0 |
7/2007 | TargeGen | Series D | 40M |
10/2016 | Evidation Health | Series B | 0 |
3/2008 | BrainCells | Series B | 30M |
12/2012 | Ultragenyx Pharmaceutical | Series B | 75M |
6/2011 | Milestone Pharmaceuticals | Series A | 0 |
10/2007 | Optherion | Series A | 37M |
12/2010 | TYRX | Venture Round | 20M |
8/2007 | FlowCardia | Series C | 0 |
3/2015 | Balance Therapeutics | Series A | 18M |
6/2007 | Gentis | Series A | 10M |
8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
3/2015 | Aura Biosciences | Series B | 0 |
7/2010 | Liquidia Technologies | Series C | 5M |
2/2011 | Chimerix | Series F | 45M |
11/2007 | LEAD Therapeutics | Series A | 17M |
12/2009 | Afferent Pharmaceuticals | Series A | 23M |
1/2006 | CoLucid Pharmaceuticals | Series A | 0 |
1/2015 | CoLucid Pharmaceuticals | Series C | 0 |
8/2011 | CoLucid Pharmaceuticals | Venture Round | 0 |
7/2008 | CoLucid Pharmaceuticals | Series B | 0 |
10/2018 | VelosBio | Series A | 0 |
7/2017 | Kezar Life Sciences | Series B | 0 |
10/2016 | Evidation Health | Series B | 0 |
8/2016 | Rotation Medical | Series B | 0 |
6/2015 | Milestone Pharmaceuticals | Series B | 0 |
3/2015 | Thrasos | Series D | 0 |
3/2015 | Balance Therapeutics | Series A | 0 |
3/2015 | Aura Biosciences | Series B | 0 |
1/2015 | CoLucid Pharmaceuticals | Series C | 0 |
7/2014 | Rotation Medical | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|